Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases

Table 3

Factors associated with prolonged survival among patients with neuroendocrine liver metastases on multivariable analysis.

Variable	HR	95% CI	value
Hospital type: Community Cancer Program	1.43	1.08 - 1.88	0.01
Hospital type: Comprehensive Community Cancer Program	1.24	1.05 - 1.48	0.01
Hospital type: Integrated Network Cancer Program	1.46	1.14 - 1.88	0.003
Hospital type: Academic/Research Program	1
Charlson: score 2	1.70	1.24 - 2.32	<0.001
Charlson: score 1	1.22	0.96 - 1.54	0.11
Charlson: score 0	1
Extrahepatic metastases	1.76	1.40 - 2.22	<0.001
No extrahepatic metastases	1
Before 22 months
years	2.18	1.76 - 2.69	<0.001
years	1
Surgery: none	1
Surgery: distant site only	0.57	0.30 - 1.08	0.09
Surgery: primary site only	0.36	0.28 - 0.46	<0.001
Surgery: debulking	0.23	0.17 - 0.31	<0.001
After 22 months
years	1.37	1.05 - 1.78	0.02
years	1
Surgery: none	1
Surgery: distant site only	1.05	0.46 - 2.43	0.90
Surgery: primary site only	0.58	0.42 - 0.78	<0.001
Surgery: debulking	0.43	0.31 - 0.61	<0.001